Cantor Fitzgerald, L. P. Mereo Biopharma Group PLC Transaction History
Cantor Fitzgerald, L. P.
- $4.65 Billion
- Q1 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 355,000 shares of MREO stock, worth $958,500. This represents 0.02% of its overall portfolio holdings.
Number of Shares
355,000
Previous 225,000
57.78%
Holding current value
$958,500
Previous $787,000
1.4%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding MREO
# of Institutions
100Shares Held
112MCall Options Held
1MPut Options Held
668K-
Janus Henderson Group PLC London, X022.7MShares$61.4 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$41.3 Million0.99% of portfolio
-
Mangrove Partners New York, NY8.64MShares$23.3 Million3.05% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.82MShares$21.1 Million1.11% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$18.1 Million0.38% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $337M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...